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Abstract
Background: The purpose of present work is to synthesize novel (+)-Dehydroabietylamine derivatives (DAAD) using
N-acetyl-α-amino acid conjugates and determine its cytotoxic effects on hepatocellular carcinoma cells.
Methods: An analytical study was conducted to explore cytotoxic activity of DAAD on hepatocellular carcinoma cell
lines. The cytotoxicity effect was recorded using sulforhodamine B technique. Cell cycle analysis was performed using
Propidium Iodide (PI) staining. Based on cell morphology, anti growth activity and microarray findings of DAAD2
treatment, Comet assay, Annexin V/PI staining, Immunoperoxidase assay and western blots were performed accoringly.
Results: Hep3B cells were found to be the most sensitive with IC50 of 2.00 ± 0.4 μM against (+)-N-(N-Acetyl-L-Cysteine)-
dehydroabietylamine as DAAD2. In compliance to time dependent morphological changes of low cellular confluence,
detachment and rounding of DAAD2 treated cells; noticeable changes in G2/M phase were recorded may be leading
to cell cycle cessation. Up-regulation (5folds) of TUBA1A gene in Hep3B cells was determined in microarray
experiments. Apoptotic mode of cell death was evaluated using standardized staining procedures including comet
assay and annexin V/PI staining, Immuno-peroxidase assay. Using western blotting technique, caspase dependant
apoptotic mode of cell death was recorded against Hep3B cell line.
Conclusion: It is concluded that a novel DAAD2 with IC50 values less than 8 μM can induce massive cell attenuation
following caspase dependent apoptotic cell death in Hep3B cells. Moreover, the corelation study indicated that DAAD2
may have vital influence on cell prolifration properties.
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Background
Hepatocellular carcinoma (HCC) is the most common
primary liver cancer. It is the fifth most frequent
neoplasm and the third largest mortality causing cancer
[1, 2]. The average life of HCC is 6 months after diagno-
sis including surgical treatment options, suggesting poor
prognosis of the disease [1–3]. However, the highest in-
cidence of HCC reported in Asia and Africa [4]. Thus, it
is an alarming situation that annually around about
600,000 individuals lost their lives due to HCC and al-
most the same number of new cases registered every
year [5, 6]. The HCC in humans can be caused by multi-
factors such as: high intake of alcohol and Aflatoxin,
hereditary disorders and chronic infections with HCV
and HBV [7, 8]. These factors have direct impact on pa-
tient characteristics as well as the tumor progression [9].
The traditionally available therapies (chemotherapy or
surgery) for the treatment of HCC are still not very
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successful in terms of quality and survival. However, So-
rafenib is the first oral multikinase inhibitor and only
the approved drug by Food and Drug Administration
(FDA) for the treatment of HCC [10, 11]. These disap-
pointing facts and figures suggested a dire need of effect-
ive drugs for the treatments of HCC.
Considering that structural manipulation is still re-
markable and effective technique for the enhancement
of drug efficacy and associated with the finding of novel
drugs with potentially broad bioactive spectra. The
(+)-Dehydroabietylamines (DAA) and its derivatives re-
ported for biological activities including cytotoxic effects
[12–15], endo-peptidase inhibitory activity, antibacterial
[16, 17], antitumoral [18], and anti-carcinogenesis activ-
ity [19].
N-acetyl amino acids may have a fundamental role in
several physiological and biochemical functions of the
human body [20]. Therefore, currently seven N-acetyl
amino acids were used to synthesize seven derivatives of
DAA through the association of peptide linkage between
primary amine of DAA and carboxylic acid of N-acetyl
amino acids. Meanwhile, the proposed drugs may have
greater than 25% carboxamide functionality [20]. How-
ever, the carbodiimide mediated peptide coupling
method remains to be the most frequently used tech-
nique, as a major advantage, the carbodiimide did not
require prior activation of carboxylic acid [20]. Thus, the
purpose of this study was first to synthesize seven deriv-
atives of DAA using seven N-acetyl amino acids and
their characterization by different analytical techniques.
Moreover, the proposed novel (+)-Dehydroabietylamine
analogues were used to examine the in vitro cytotoxicity
of one breast cancer and ten HCC cell lines in detail.
Methods
Reagents and apparatus
All reagents and chemicals used during experimental
work were analytical grade. The N- N-acetyl amino
acids, (+)-Dehydroabietylamine, dehydroabietylamine,
dichloromethane, dicyclohexyl carbodiimide, 4-dimethyl
amino pyridine, ethanol, methanol and ethyl acetate pur-
chased from Sigma–Aldrich (St. Louis, MO, USA). DMSO
was obtained from Applichem Biochemica (Darmstadt,
Germany). Analytical thin-layer chromatography was per-
formed on precoated silica gel plates (Merck PF254,
Darmstadt, Germany) and detection of spots were made
by UV light and/or iodine vapors. Silica gel 60 (Merck,
particle, size 0.040–0.063 mm, 230–240 mesh) was used
for preparative column chromatography.
IR spectra were recorded on a Thermo-Nicolet 5700
Fourier transform infrared (FTIR) spectrometer (Fitch-
burg, WI) with KBr pellets. NMR spectra were recorded
at room temperature on Bruker AM instrument operating
at 400 and 500 MHz (1H). Residual solvent signals are
internally referenced. Chemical shifts δ is referred in terms
of ppm, coupling constants J are given in Hz. Following
abbreviations classify the multiplicity: s = singlet, d =
doublet, t = triplet, q = quartet, m =multiplet or unre-
solved, br = broad signal. Infrared spectra were recorded
on a Schimadzu system and reported in cm−1. Samples
were prepared in thin film technique. Mass spectra were
done using the facilities in laboratories of HEJ Research
institute of Chemistry, University of Karachi.
Synthesis
General procedure for the preparation of Amides from
amino acids (DAAD 1–7)
To a solution of dehydroabietylamine (1 mol) in dichlo-
romethane, dicyclohexyl carbodiimide (DCC, 1 mol), 4-
dimethyl amino pyridine (DMAP, 0.5 mol) and N-acetyl
amino acids (1 mol) were added, the resulting mixture
was stirred at room temperature for 2 h. After comple-
tion of reaction 50 ml of ethyl acetate was added and
filter. Filtrate washed with water (20 ml×2), and dried
over anhydrous Na2SO4 and the solvent removed by
evaporation. The formations of DAAD (1–7) were moni-
tored by TLC; the compound was extracted from reaction
mixture and characterized by applying different spectro-
scopic techniques. Formation of amide was completed in 2
to 2.5 h. N-acetyl-α-amino acid conjugates of (+)-Dehydroa-
bietylamine (DAA) were prepared using Glycine, L-Cysteine,
L-Methionine, L-Tyrosine, L-Aspartic acid, L-Phenylalanine
and L-Alanine to furnish amides 1–7 respectively. All
amides were obtained in good yields. The structure
confirmation of compounds 1–7 was carried out (Additional
file 1: Suppl. data Chemistry and Additional file 2:
Characterization and Synthesis) using spectroscopic
techniques including ESI-MS, FTIR, 1H-NMR, 1D & 2D,
13C-NMR, COSY, HMBC, HSQC and NOESY spectroscopy.
Cell lines care and cytotoxicity screening protocol
Ten HCC cell lines including Huh7, Hep3B, Hep3B-TR,
HepG2, Hep40, SNU449, Mahlavu, PLC/PRF/5, SNU387,
SNU475 and one breast cancer line MCF7 cryogenically
stored in a liquid nitrogen Tank. Sulforhodamine B (SRB)
method has been implemented for in vitro primary
screening [21, 22]. Initially, a HCC cell line Huh7 and one
breast cancer line MCF7 were used for primary screening
of trial drugs (seven derivatives of synthesized DAA). For
both Huh7 and MCF7 cell lines, 2000 cells/well were cul-
tured in 96 well plate in incubator at 37 °C with 5% CO2
in complete medium (DMEM, 10% FBS, 1% NEA, 1% L-
Glutamine and 1% P/S) and incubated for 24 h. All stock
solutions were prepared in 100% DMSO with a concentra-
tion of 20 mM. Further dilutions were made with the help
of respective media for each cell line. After 24 h, all trial
drugs were introduced in two different (50 μM and
10 μM) concentrations in triplicate for each sample and
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plates were further incubated for next 72 h. After 72 h,
media discarded and cells were washed once by using
1XPBS.
For fixation, 50 μL of ice cold 10% TCA was added
into each well and kept in dark at 4 °C for 1 h. After fix-
ation, the TCA was removed by tapping and plates were
washed 4–5 times with ~200 μL dH2O. Plates were left
over night for drying under hood. Finally, 50 μL of 0.4%
SRB in 1% acetic acid solution was added to each well
and left at room temperature for 10 min. Excessive SRB
dye was removed and the plates washed 4–5 times with
1% acetic acid before air drying. Bound SRB dye was sol-
ubilized with 100 μL of 10 mM un-buffered chilled tris-
base solution and plates were left on a plate shaker for
at least 1–2 min. Absorbance was recorded using μ-
Quant microplate reader with a wave length range of
405–515 nm. The test OD values were defined as the
absorbance of each sample. Mean values were deter-
mined and standard deviation was found satisfactory
ranging in between 0.001 to 0.25 in all respective sam-
ples from triplicates wells which were calculated auto-
matically using MS Office Excel 2007 (v14.0) software
for Windows.
Measurement of cell morphology
Six-well plates were used for photographs and 3 × 105
cells were maintained in each well, after 24 h drug was
administered. Photographs of most sensitive (Hep3B)
cell line were taken during three consecutive intervals
i.e., 24, 48 and 72 h and compared with DMSO controls.
All photographs were taken at 10X and 20X using a light
microscope.
Cell proliferation assay
Cells were plated in 10 cm2 Petri plates at 3–4 × 105 per
plate. After drug treatment, cells were harvested in dif-
ferent intervals by trypsinization and washed with PBS.
Cells were fixed in ice-cold 70% ethanol, washed, and re-
suspended in 3 mL of 70% ethanol for storage at 4 °C;
fixed cells treated with RNase A; and stained with propi-
dium iodide (PI) for 45 min at room temperature. The
stained cells were analyzed by flow cytometry using BD
FACScalibur™.
Comet assay [23]
Hep3B cell line was used and around 200,000 cells/well
were seeded in six well plates. Adriamycin (1 μM), and
Camptothecin (5 μM) were used as positive controls.
DAAD2 was administered in two different concentra-
tions (5uM and 10 μM). Drugs were given to cells after
24 h of seeding. Both treated and untreated samples
were collected after 24,48 and 72 h from plates through
scraper with whole media after centrifugation at
1000 rpm for 10 min at +4 °C.
Freshly prepared 100 mL 1% normal melting agarose
poured into a jar and kept in a water bath at 50–55 °C.
The slides were placed into jar vertically and kept for
about 15–20 min at room temperature. 15 ml of 0.7%
low melting agarose (LMA) was also prepared and kept
it at 4 °C. Both controls and treated cells were taken
from incubator and washed with 1X cold PBS once.
2 mL of 1XPBS for each well of 6 wells plate added and
cells were transferred directly in to 15 mL falcon tubes.
The cells were centrifuged at 1000 rpm for 6 min at 4 °
C. Supernatant was discarded and pallet of the cells re-
suspend with cold PBS (700 μL) without bubbling. 5–
10 μL cell suspension was put on already prepared 1%
agarose coated slide, and coated with 70–80 μL LMA
with cover slip (24 × 50 mm) onto the cells. Cells were
counted under the microscope to validate the desired
cell number and stored for 12–15 min at 4 °C to allow
LMA layer to soluble. For third layer, again 70–80 μL of
LMA covered with cover slip was used for coating, and
the slides were kept at 4 °C for about 12–15 min. Slides
were pour in to tank for at least 1 h containing lysis buf-
fer and importantly temperature was maintained at 4 °C.
Slides were taken out and washed with neutralization
buffer thrice. In the next step, freshly prepared electro-
phoresis buffer (0.555 g Na-EDTA + 10 g NaOH cold
1.5 L dH2O maintained at 4 °C) was poured into electro-
phoresis tank and the tank was covered with ice to
maintain the temperature before use. The washed slides
were placed without any gap into the tank as writing
place of slides on positive side of the electrode. Power
supply for electrolysis tank was maintained on 25 V and
maximum up to 280 A. Incubation of the slides was
done in dark with electrophoresis buffer for 20 min to
denature DNA and then DNA was run at 25 V per 260–
280 A per 20 min. At last, slides were taken out and
washed with neutralization buffer thrice gently and kept
slides into the buffer until DAPI staining. For DAPI
staining, 45 μL, (5 μg/mL DAPI) with 24 × 50 mm cover-
slip onto the slides was applied and kept into the humid-
ity chamber at (papers with water) 4 °C before taking
the pictures on fluorescent microscope.
Propidium iodide staining [24]
Hep3B cells were maintained in 5 cm2 Petri plates and
cover slips were added at the time of splitting. After
24 h, DAAD2 (2 μM & 5 μM) was supplemented. While,
media with less than 0.1% DMSO were also changed for
negative controls. After 72 h of incubation, cover slips
from both control and sample were taken out and as per
given protocol cover slips were covered with annexin V/
PI staining solution for 15 min. Photographs were taken
at fluorescent microscope with detection range of 515–
565 nm (green).
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Microarray gene-expression analyses [25, 26]
Affymetrix Human Genome U133 Plus 2.0 Gene-Chips
were used for whole-genome gene expression profiling
experiments. Isolated total RNAs of treated and non-
treated DAAD2-sensitive HEP3B and DAAD2-resistant
SNU449 cells processed according to manufacturer’s in-
structions. Quality control analyses of microarray data
performed using the BRB Array Tools V 4.2.0 (http://
linus.nci.nih.gov/BRB-ArrayTools.html). Triplicate sam-
ples from each sample type (12 samples in total) were
used for the rest of the analyses. Normalizations of the
raw data obtained from Gene-Chip Operating Software
performed using the BRB Array Tools.
Lists of differentially expressed genes were determined
using the Class Comparison Tool of the BRB Array
Tools software. Genes differing more than 1.5 fold be-
tween control and DAAD-2 treated Hep3B cells, as well
as control and DAAD-2 treated SNU449 cells were de-
termined in separate lists.
Lists of differentially expressed genes were further ana-
lyzed via Connectivity Map (cmap) Tool [27] to further
investigate molecular mechanisms responsible for resist-
ance and sensitivity to DAAD-2 treatments. Gene ex-
pression signatures of drug-sensitive and drug-resistant
HCC cells were used to determine similarities with sig-
natures of previously characterized chemicals in the
cmap database.
Immuno-peroxidase assay [28]
Hep3B cells were plated for 24 h in 12 well/plates at
50,000 cells on cover-slips for per each well. After
DAAD2 treatment (2 μM & 5 μM) of 48 h, medium was
aspirated. Cells were fixed with acetone and methanol
mix solution (1:1) at −20 °C for 10 min. After aspiration
of fixation solution, three times washing with 1XPBS
performed for each plate. Hydrogen peroxide was added
and hold for 10 min at room temperature in dark to
block endogenous per oxidase activity. Washing step
was repeated thrice again. Blocking was done using 10%
FBS and 0.3% Triton X-100 in 1X PBS solution for 1 h
in dark at room temperature. Anti human Caspase-3
(cleaved) was diluted in blocking solution (1:1000) and
100 μl of primary antibody was added on top of the
cover slip drop by drop. After overnight incubation at
4 °C, cover-slips were washed with 1X PBS-T solution.
80 mL of Dako Envision secondary antibody was added
on the top of the coverslips drop by drop and incubated
in dark for 1 h at room temperature. Washing with 1X
PBS-T solution performed twice. DAB solution was pre-
pared and used as per manufacture guidelines. Counter-
staining with hematoxylin solution was done for 5 min.
at room temperature. After vigorous washing, coverslips
were stained with blueing solution (0.1% Sodium Bicar-
bonate in distilled water) for 1 min at room temperature
and rinsed with water. Finally, 85% of glycerol was added
on top of each coverslip and put upside down on glass
slide.
Western blotting [29]
To determine the protein level of differentially expressed
genes of interest, cells were treated with 2 μM dose of
DAAD2 for 72 h and the lysed with a Radioimmunopreci-
pitation Assay (RIPA) Buffer. Concentrations of protein ly-
sates were measured by the conventional Bradford assay
utilizing spectrophotometer at 595 nm. Sample protein
concentrations were normalized in accordance with bo-
vine serum albumin (BSA) standard curve. Around 30 μg
of total proteins were subjected to gel electrophoresis
using NuPAGE system with MES and/or MOPS buffers.
Proteins were wet-transferred onto HyBond ECL nitrocel-
lulose membranes. The membranes were blocked for 1 h
at room temperature with 5% BSA in TBS-T. Membranes
were incubated with the primary antibodies either at room
temperature or at 4 °C for overnight. Following primary
antibody incubations and extensive washing with TBS-T,
secondary antibodies conjugated with horse-radish perox-
idase (HRP) incubated 1 h at room temperature. After an
additional wash of half an hour with TBSt-T, chemilumin-
escent reaction was recorded using ECL prime western
blot detection kit (Thermoscientific), as per manufac-
turer’s guidelines. X-ray films were exposed to the emitted
chemiluminescence.
Statistical analysis
The 19th version of SPSS (SPSS, Chicago, IL, USA) and
Microsoft Excel 2007 (Roselle, IL, USA) were used for
the statistical and graphical evaluations. Data were col-
lected and expressed as the mean ± standard deviation of
three independent experiments. Statistical analysis was
performed by correlation of determination (R2) and
probability test.
Results and discussion
Growth attenuation experiments and IC50 determination
In recent study, synthesized seven DAA derivatives
(DAAD 1–7) were screened for cytotoxic effect on
breast cancer and HCC cell lines by SRB technique as
described in experimental part. Based on primary
screening results (Fig. 1 and Additional file 3: Figure S1),
DAAD 2 with a functional site of N-acetyl cysteine
group at C-18 (2R) was found to be the most potent
with 100% growth attenuation at 50 μM and 10 μM con-
centration on both Huh7 and MCF7 cells. Thus, it was
selected for further investigation of cytotoxic effect and
its mechanism. In continuation, IC50 values of DAAD2
were determined for all cell lines. All cells were treated
with DAAD2 at different concentrations in triplicates
ranging from 10 μM to 0.313 μM; for controls up to
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0.1% DMSO final concentration was maintained with re-
spective media for each cell line; camptothecin (CPT) as
a positive control was used in triplicate at 5 μM concen-
tration for all experiment. The IC50 values against all cell
lines calculated using OD values against each drug con-
centration. Camptothecin showed around 80% growth
attenuation at 5 μM concentration on Hep3B cells.
While, inhibition rate of camptothecin found more than
90% on rest of cell cells lines.
As presented in Table 1, except SNU449 cell line with
IC50 value more than 10 μM; all other cell lines showed
95–100% growth attenuation at 10 μM drug concentra-
tion of DAAD2, with IC50 range from 2 to 8 μM; indi-
cating that this drug might have comparatively extensive
therapeutic index than other trial drugs of the study.
According to Table 1 and graph curve (Fig. 1b), Hep3B
cells found to be the most sensitive cell line with the
IC50 value of 2.0 ± 0.4 μM and reported around 90% in-
hibition at 5 μM drug treatment after 72 h.
Morphology using light microscopy
Hep3B cells were treated with DAAD2 on 10 cm2 Petri
plates; using a light microscope the differences in cell
morphology was observed in DAAD2 treated and un-
treated cells. Photographs were taken at 20X after 24, 48
and 72 h consecutively. Noticeable morphological
changes resulting from low cell confluence, enlarged nu-
clei, cell rounding and loss of cellular attachment were
observed at 24 h. The extent of these morphological
changes gradually increased from 24 to 72 h of drug
Fig. 1 a Primary SRB (sulforhodamine B) screening results: Cytotoxic effects of seven novel compounds labeled as 1–7 (concentration of 50 μM
and 10 μM), on Huh7 and MCF7 cell lines. b Molecular structure and cytotoxic activity with IC50 values of DAAD2 on 10 HCC and one breast
cancer cell lines
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treatment. These morphological changes suggested fur-
ther biochemical and molecular investigation to rational-
ize these morphological outcomes (Fig. 2).
G2/M phase arrest after 48 and 72 hours
To further validate inhibitory influence of our most po-
tent trial drug DAAD2; cell cycle proliferation technique
was adopted for quantitative analysis of cell progression
in comparison with DMSO control. As described in
methods part, Hep3B cells were studied accordingly.
The percentages of cells in each phase of the cell cycle
(Sub G1/G0, G1, S and G2/M) were determined 24, 48
and 72 h after treatment. As shown in Fig. 3, after 24 h
of DAAD2 treatment although there was no significant
change reported in G2/M phase. But after 48 and 72 h
of DAAD2 treatment, significant (p < 0.001) decrease in
the proportion of cells in G2/M phase; and nine-fold in-
crease (p < 0.001) was recorded in sub-G1 phase after 48
and 72 h. In contrast, there was no noticeable change re-
corded (p > 0.05) in S phase after 48 and 72 h, whereas
the percentage of G1 phase cells also decreased (p <
0.05) in DAAD2 treated cells (Fig. 3).
Alkaline comet assay
We performed alkaline comet assay to see the tail move-
ment of single stranded DNA breaks. Hep3B cell line
was used and around 200,000 cells/well were seeded in
six well plates. Adriamycin (1 μM), and Camptothecin
(5 μM) were used as positive controls. Trial drug
DAAD2 was administered in two different concentra-
tions (5 μM and 10 μM). Photographs were taken after
24, 48 and 72 h. No obvious alkaline comets were seen
by applying trial drug DAAD2 on Hep3B cells (Fig. 4a).
At 10 μM of DAAD2 drug administration, 24 and 48 h
photographs were taken. But DAPI stained cells were
not seen after 72 h and therefore photographs were not
taken. The rapid growth attenuation was observed at
10 μM DAAD2 drug administration’s on Hep3B cells.
Both Adriamycin and Camptothecin showed obvious al-
kaline comets. The DAAD2 treated cells (after 48 and
72 h) at 5 μM showed neutral comets may be of double
stranded DNA breaks. (Fig. 4a)
Class comparison and connectivity Map approach
In order to be able to determine molecular effects of
DAAD2 treatment to liver cells, we determined whole-
genome transcriptome profiles of DAAD2 treated and
untreated (control) Hep3B and SNU 449 cells. Class
comparison analyses using microarray data of DAAD2-
sensitive Hep3B cell line (Additional file 4: Table S1),
and DAAD2-resistant SNU449 cell line (Additional file
5: Table S2) provided the lists of genes differentially
expressed as a result of DAAD2 treatments. Using
Table 1 IC50 Values of 11 cell lines using Trial Drug (DAAD2)
Cell Lines IC50 Value of DAAD2
(μM conc.)
R2
Hep3B 2.0 ± 0.4 0.9
MCF7 2.2 ± 0.8 0.8
PLC 2.8 ± 0.6 0.9
Hep3B-TR 3.2 ± 0.8 0.8
Hep40 3.5 ± 1 0.8
SNU387 3.6 ± 0.6 0.8
SNU475 4.4 ± 0.6 0.7
Mahlavu 5.2 ± 0.9 0.6
Huh7 6.4 ± 2 0.6
HepG2 7.6 ± 0.8 0.5
SNU449 27.5 ± 5 0.7
Fig. 2 Cell Morphology of DAAD2 treated and untreated cells: Noticable morphological changes resulting from low cell confluency and loss of
cellular attachment with rounding of cells is depicted. The time dependent pattern of these morphological changes from 24 to 72 h can be seen
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differentially expressed gene results of drug-sensitive
Hep3B and drug-resistant SNU 449 cells the connect-
ivity map (cmap) analyses employed to determine the
lists of previously characterized drugs that show simi-
lar and different gene expression profiles as a result
of DAAD2 treatment. The Additional file 6: Figure S3
showed top 20 drugs with similar gene expression
changes. Cmap analyses suggests that DAAD2 treat-
ment triggers similar gene expression alterations as
vinburnine does [30], since vinburnine and DAAD-2
treatments caused similar gene expression changes in
drug-sensitive Hep3B cells, but highly different gene
expression alterations in drug-resistant SNU449 cells
(Additional file 7: Figures S2 and Additional file 6:
Figures S3). In addition, we recorded more than 5-
fold up regulation of TUBA1A gene in Hep3B treated
cells, which has significant role in spindle formation
at mitotic stage of cell cycle (Additional file 4: Table
S1). To validate that DAAD2 may have some signifi-
cant role to diverge the G2/M phase of cell prolifera-
tion, conformational studies were required.
Apoptosis study of Hep3B cells
In recent era, Annexin V/Propidium iodide (PI) protocol
is considered to be one of the commonly used approach
for identification of apoptotic cells [24]. Annexin V in
combination with PI is widely used to determine cell via-
bility, apoptosis, or necrosis through deviations in per-
meability and integrity of plasma membrane. Due to
stable, inexpensive, ability to not enter into the nucleus
of live cells and believe to be a good indicator for cell
viability than other available nuclear stains, PI is more
commonly used. As shown in Fig. 4b, DAAD2 treated
Hep3B cells showed high apoptotic mode of cell death
at two different concentrations (2 μM & 5 μM).
Caspase dependent apoptotic mode of cell death
Cysteine aspartate proteases commonly known as cas-
pases have very vital role in initiation and execution of
apoptotic process inside the cell. Therefore, based on
above mentioned cell progression results [31], we per-
formed Immuno-peroxidase assay on DAAD2 treated
cells to determine the role of caspase-3 cleaved. It is re-
ported that after initial activation of acaspase-9, ROS
production is inhibited by caspase-3 [28] essentially
needed for programmed cell death. As presented in
Fig. 4c, low activation of caspase-3 cleaved was observed
at 2 μM, while at 5 μM after 48 h of DAAD2 treatment
all cells were unstained and mortal; unable us to identify
the role and conclude the activation of caspase-3.
Because of weak positive findings of caspase-3 cleaved
through Immuno-peroxidase assay; we further evaluated
role of caspase-3 cleaved using western blotting tech-
nique. Results were also validated through equal loading
of calnexin [29]. (Figure 5) Our findings significantly
highlight the activation of caspase-3 cleaved (17kda) in
DAAD2 treated cells, while no sign of activation of same
enzyme were observed in controls (untreated).
Fig. 3 Cell cycle results after 24, 48 and 72 h of DAAD2 (5 μM concentration) treated Hep3B cells and DMSO controls (up to 0.1%) as untreated
cells. Comparative to un-treated Hep3B cells, noticeable changes in sub-G1/G0 and G2/M phase of DAAD2 treated Hep3B cells are shown
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Fig. 4 a Comet assay for DNA breaks: DAAD2 (5 μM), adriamycine (1 μM), camptothecin (5 μM) and DMSO controls (up to 0.1%). Photographs
were taken after 72 h; obvious alkaline comets are shown in Hep3B cells treated with adriamycine and camptothecin. b Annexin V/PI Staining:
DAAD2 (2 & 5 μM), camptothecin (5 μM) and DMSO controls (up to 0.1%). Photographs were taken after 72 h. DAAD2 treated Hep3B cells
showed the apoptotic mode of cell death. c Immunoperoxidase Assay: Compound DAAD2 (2 & 5 μM), camptothecin (5 μM) and DMSO controls
(upto 0.1%). Photographs were taken after 48 h. DAAD2 (2 μM) treated cells showed weak activation of caspase-3 cleaved
Fig. 5 Western Blotting: DAAD2 (2 μM) and DMSO controls (up to 0.1%). Findings after 72 h of DAAD2 treatments. DAAD2 treated cells showed
activation of caspase-3 (cleaved). In addition, calnexin was used as an equal loading control
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Conclusions
In the first part of this study seven new (+)-Dehydroa-
bietylamine derivatives with N-acetyl-α-amino acids at
C-18 on ring A were synthesized, purified and character-
ized. In the second part, cytotoxic effects were recorded
in a dose dependent manner for each new derivative.
DAAD2 ((+)-Dehydroabietylamine with N-acetyl cyst-
eine in ring A at C-18) was found to be the most potent
among all trial drugs of the study; subjected for cyto-
toxic effects on ten HCCs and one breast cancer cell
line. Hep3B cells were the most sensitive with IC50 of
2.00 ± 0.4 μM against DAAD2. Similarly, obvious mor-
phological deviations and significant time dependent
changes in sub-G1 (8–9 fold increase) and G2/M phase
(2 fold decrease) in Hep3B cells after 48 and 72 h of
DAAD2 treatments were recorded.
Whole-genome gene expression microarray data of
DAAD2-sensitive and DAAD2-resistant HCC cells re-
vealed that DAAD2 treatment cause similar gene expres-
sion alterations in HCC cells as vinburnine does to PC3
cells [Additional file 4: Table S1 and Additional file 5:
Table S2]. Unfortunately, there are no comprehensive data
on molecular functions of vinburnine to help us under-
stand the molecular effects of DAAD2 on HCC cells. The
DAAD2 showed caspase dependent apoptotic mode of
cell death. The present outcomes exhibit the structural
significance of our trial novel drug, its vital influence and
correlation on cytotoxic and anti cancer properties.
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